EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS

TOKYO, March 5, 2024 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC (Headquarters: St. Louis, Missouri, the United States “C2N”) to…